Treatment response to sunitinib in imatinib-resistant recurrence of dermatofibrosarcoma protuberans on the capillitium

被引：0
|
作者：
Mueller, C. [1 ]
Scheib, C. [1 ]
Peller, V. [1 ]
Zillikens, H. [1 ]
Rudolph, V. [1 ]
Leven, A. S. [1 ]
Bauer, S. [2 ]
Pretzell, I. [3 ]
Griewank, K. [1 ]
Sucker, A. [1 ]
Hadaschik, E. [1 ]
Roesch, A. [1 ,2 ]
Ugurel, S. [1 ]
Schadendorf, D. [1 ,2 ]
Zimmer, L. [1 ]
Livingstone, E. [1 ]
机构：
[1] Univ Klinikum Essen, Dermatol, Essen, Germany
[2] Deutsches Konsortium Translat Krebsforsch DKTK, Essen, Germany
[3] Univ Klinikum Essen, Westdeutsches Tumorzentrum, Essen, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP119
引用
收藏
页码：99 / 100
页数：2
相关论文
共 50 条
  • [1] Abscopal Effect of Radiotherapy in Imatinib-resistant Dermatofibrosarcoma Protuberans
    Agyeman, Mervin B.
    Vanderpuye, Verna D.
    Yarney, Joel
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (01)
  • [2] Genetic Aberrations in Imatinib-Resistant Dermatofibrosarcoma Protuberans Revealed by Whole Genome Sequencing
    Hong, Jung Yong
    Liu, Xiao
    Mao, Mao
    Li, Miao
    Choi, Dong Il
    Kang, Shin Woo
    Lee, Jeeyun
    Choi, Yoon La
    PLOS ONE, 2013, 8 (07):
  • [3] Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib
    Fu, Yan
    Kang, Huanrong
    Zhao, Hui
    Hu, Jia
    Zhang, Huanhuan
    Li, Xiaosong
    Du, Nan
    Huang, Yitao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 8288 - 8294
  • [4] Imatinib in the treatment of dermatofibrosarcoma protuberans
    Labropoulos, Stefanos V.
    Razis, Evangelia D.
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04): : 347 - 353
  • [5] IMATINIB, IN THE TREATMENT OF DERMATOFIBROSARCOMA PROTUBERANS
    Fattoruso, S. I. S.
    Lopez, M.
    EJC SUPPLEMENTS, 2008, 6 (14): : 145 - 145
  • [6] Sunitinib for imatinib-resistant GIST
    Joensuu, Heikki
    LANCET, 2006, 368 (9544): : 1303 - 1304
  • [7] A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
    Xiao, Wei
    Que, Yi
    Peng, Ruiqing
    Ding, Ya
    Zhao, Jingjing
    Wen, Xizhi
    Weng, Desheng
    Zhang, Xiaoshi
    Guan, Yuanxiang
    Zhang, Xing
    ONCOTARGETS AND THERAPY, 2018, 11 : 2439 - 2443
  • [8] Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment
    Tazzari, Marcella
    Indio, Valentina
    Vergani, Barbara
    De Cecco, Loris
    Rini, Francesca
    Negri, Tiziana
    Camisaschi, Chiara
    Fiore, Marco
    Stacchiotti, Silvia
    Dagrada, G. Paolo
    Casali, Paolo G.
    Gronchi, Alessandro
    Astolfi, Annalisa
    Pantaleo, Maria A.
    Villa, Antonello
    Lombardo, Claudia
    Arienti, Flavio
    Pilotti, Silvana
    Rivoltini, Licia
    Castelli, Chiara
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (02) : 484 - 493
  • [9] Dermatofibrosarcoma protuberans: A partial response to imatinib therapy
    Mehrany, K
    Swanson, NA
    Heinrich, MC
    Weenig, RH
    Lee, KK
    White, CR
    Devere, TS
    DERMATOLOGIC SURGERY, 2006, 32 (03) : 456 - 459
  • [10] Genomic analyses and novel models validate CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans
    Marino-Enriquez, Adrian
    Eilers, Grant
    Czaplinski, Jeffrey
    Mayeda, Mark
    Tao, Derrick
    Zhu, Meijun
    Hornick, Jason L.
    Sicinska, Ewa
    Wagner, Andrew J.
    Fletcher, Jonathan A.
    CANCER RESEARCH, 2015, 75
12345